3-chloro-6,7,8,9-tetrahydro-5H-benzo[a]cycloheptan-6-one | 34658-46-3

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 3-chloro-6,7,8,9-tetrahydro-5H-benzo[a]cycloheptan-6-one
• 英文别名: 3-chloro-5,7,8,9-tetrahydrobenzocyclohepten-6-one；8-Chlor-2-benzosuberon；3-chloro-5,7,8,9-tetrahydrobenzo[7]annulen-6-one
• CAS: 34658-46-3
• 化学式: C₁₁H₁₁ClO
• 分子量: 194.661
• InChiKey: HPZNOUUJGMWJFJ-UHFFFAOYSA-N

物化性质

• 沸点：
  320.3±42.0 °C(Predicted)
• 密度：
  1.198±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-chloro-6,7,8,9-tetrahydro-5H-benzo[a]cycloheptan-6-one 在 盐酸 、 ammonium acetate 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 为溶剂， 生成 9-chloro-2-phenyl-5,6-dihydro-4H-1,3-diazabenzo[e]azulen-1-ol
  参考文献：
  名称：

  Novel potent antagonists of human neuropeptide Y-Y5 receptor. Part 4: tetrahydrodiazabenzazulene derivatives

  摘要：

  Novel tetrahydrodiazabenzazulene derivatives. designed from the lead compound 1 discovered by screening of our in-house chemical library, were prepared and found to be potent neuropeptide Y-Y5 (NPY-Y5) receptor antagonists. The structure-activity relationships are described. Compounds 7 (FR240662) and 16 (FR252384) were especially attractive owing to their high affinities for the NPY-Y5 receptors, oral absorption and permeability to brain. (C), 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00090-2
• 作为产物：
  描述：

  2-γ-Cyanopropyl-5-chlorbenzonitril 在 硫酸 、 sodium 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 3-chloro-6,7,8,9-tetrahydro-5H-benzo[a]cycloheptan-6-one
  参考文献：
  名称：

  Rosowsky,A. et al., Journal of Heterocyclic Chemistry, 1971, vol. 8, p. 789 - 795

  摘要：

  DOI：

文献信息

• Propanolamine derivatives
  申请人：Fujisawa Pharmaceutical Co. Ltd.

  公开号：US20020120148A1

  公开（公告）日：2002-08-29

  This invention relates to new propanolamine derivatives or salts thereof represented by the following formula [I]: 1 Wherein each symbol is as defined in the specification or salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.

  这项发明涉及新的丙醇胺衍生物或其盐，其化学式如下所示：1其中每个符号如规范中定义，或具有选择性肠道交感神经兴奋作用、抗溃疡、抗胰腺炎、脂解作用、抗尿失禁和抗尿频活性的盐，以及其制备方法、包含相同的药物组合物以及用于预防和/或治疗规范中指示的疾病的方法，适用于人类或动物。
• Fused imidazole derivative
  申请人：——

  公开号：US20040198791A1

  公开（公告）日：2004-10-07

  According to the present invention, fused imidazole derivatives of the general formula: 1 wherein R 1 is a hydrogen atom, a halogen atom, hydroxy group, a lower alkyl group or a lower alkoxy group, R 2 is an aryl group, benzodioxanyl group, or 5-6 membered, monocyclic, unsaturated, heterocyclic group containing nitrogen atom(s) which may be substituted with lower alkyl, trityl or oxo, R 3 is a hydrogen atom or hydroxy group, A is a group represented by the formula: —(CH 2 ) m — or —O—(CH 2 ) m — [wherein m is an integer of 1-3] and their salts are provided.

  根据本发明，提供了一般式为：1的熔融咪唑衍生物，其中R1为氢原子、卤素原子、羟基、低碳基或低氧基；R2为芳基、苯二氧基基团或含有氮原子的5-6成员单环不饱和杂环基团，可被低碳基、三苯基或氧代取代；R3为氢原子或羟基；A为以下式子所代表的基团：—(CH2)m—或—O—(CH2)m—[其中，m为1-3的整数]及其盐。
• Process for Producing Optically Active Alcohol
  申请人：Noyori Ryoji

  公开号：US20070225528A1

  公开（公告）日：2007-09-27

  A ruthenium complex RuCl[(S,S)-Tsdpen](p-cymene) represented by a formula below and a ketone compound are placed in a polar solvent, and the resulting mixture is mixed under pressurized hydrogen to hydrogenate the ketone compound and to thereby produce an optically active alcohol:

  一个由以下公式表示的钌配合物RuCl[(S,S)-Tsdpen](p-cymene)和一个酮化合物被放置在极性溶剂中，然后在加压氢气下混合，以加氢酮化合物并因此产生一个光学活性醇。
• Use of beta 3 adrenergic receptor agonists in the treatment of dysuria
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1382333A2

  公开（公告）日：2004-01-21

  The application relates to the use of a β3 adrenergic receptor agonist selected from the group consisting of formulas (IV),(V),(VI),(VII) and (VIII) for the manufacture of a medicament for the prophylactic and/or the therapeutic treatment of dysuria. In the above formulae, the various groups, substituents and variables have the meanings given in the description.

  本申请涉及选自式(IV)、(V)、(VI)、(VII)和(VIII)组成的组中的β3 肾上腺素能受体激动剂的用途。 用于制造预防和/或治疗排尿困难的药物。在上式中，各基团、取代基和变量具有说明中给出的含义。
• PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS
  申请人：Nagoya Industrial Science Research Institute

  公开号：EP1741693B1

  公开（公告）日：2011-08-03